Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RCKT Rocket Pharmaceuticals, Inc.

休市中 09-04 16:00:00 EDT

3.86

+0.07

+1.85%

盘后3.81

-0.05-1.30%

19:30 EDT

最高3.88	最低3.73	成交量88.85万
今开3.75	昨收3.79	日振幅3.96%
总市值4.24亿	流通市值3.28亿	总股本1.10亿
成交额339.23万	换手率1.05%	流通股本8,496万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RCKT","market":"US","secType":"STK","nameCN":"Rocket Pharmaceuticals, Inc.","latestPrice":3.86,"timestamp":1788552000000,"preClose":3.79,"halted":0,"volume":888541,"hourTrading":{"tag":"盘后","latestPrice":3.81,"preClose":3.86,"latestTime":"19:30 EDT","volume":3357,"amount":12903.71,"timestamp":1788564604125,"change":-0.05,"changeRate":-0.012953,"amplitude":0.032591},"delay":0,"changeRate":0.01846965699208439,"floatShares":84960264,"shares":109774597,"eps":-0.17,"marketStatus":"休市中","change":0.07,"latestTime":"09-04 16:00:00 EDT","open":3.75,"high":3.88,"low":3.73,"amount":3392343.4462046,"amplitude":0.039578,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.17,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1424235600000,"exchange":"NASDAQ","adjPreClose":3.79,"preHourTrading":{"tag":"盘前","latestPrice":3.79,"preClose":3.79,"latestTime":"09:11 EDT","volume":54,"amount":204.73700399999998,"timestamp":1788527497635,"change":0,"changeRate":0,"amplitude":0.020317},"postHourTrading":{"tag":"盘后","latestPrice":3.81,"preClose":3.86,"latestTime":"19:30 EDT","volume":3357,"amount":12903.71,"timestamp":1788564604125,"change":-0.05,"changeRate":-0.012953,"amplitude":0.032591},"volumeRatio":0.5389196024920642,"impliedVol":2.102,"impliedVolPercentile":0.9008},"requestUrl":"/m/hq/s/RCKT","defaultTab":"news","newsList":[{"id":"1124821603","title":"Rocket Pharmaceuticals 现金及投资约2.837亿美元，预计资金跑道可延至2028年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1124821603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124821603?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:49","pubTimestamp":1786394989,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 披露其现金、现金等价物及投资总额约为2.837亿美元。基于这一财务储备，公司预期其现有资金将足以支撑运营至2028年的第二季度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146191818","title":"Rocket Pharmaceuticals 公布改良版Danon病2期临床试验中首批三名患者接受Rp-A501治疗的积极安全性更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1146191818","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146191818?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:06","pubTimestamp":1785755161,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 宣布，基于改良版2期临床试验方案，首批接受Rp-A501治疗的三名Danon病患者，其临床安全性数据呈现积极态势。此次更新标志着该试验取得了阶段性进展，为后续研究奠定了坚实基础。公司管理层对此次结果表示审慎乐观，并强调将持续监测患者长期安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107893250","title":"Rocket Pharmaceuticals：Rp-A501在首批三名患者中耐受性良好，未出现TMA或毛细血管渗漏综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1107893250","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107893250?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:02","pubTimestamp":1785754955,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals公司宣布，其候选药物Rp-A501在首批三名患者中表现出良好的耐受性。值得关注的是，在这项初步研究中，没有观察到血栓性微血管病（TMA）或毛细血管渗漏综合征的发生。这一结果标志着该药物在安全性方面迈出了积极的一步，为后续临床开发提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108020187","title":"Rocket Pharmaceuticals以1.8亿美元完成罕见儿科疾病优先审评券出售交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1108020187","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108020187?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:01","pubTimestamp":1781262078,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 已成功完成其罕见儿科疾病优先审评券的出售，交易总额为1.8亿美元。此举将为公司带来可观的非稀释性资金，用于推进其针对严重罕见疾病的基因治疗产品管线的研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119497721","title":"FDA向罕见儿科疾病产品申请方颁发优先审评券——联邦公报网站","url":"https://stock-news.laohu8.com/highlight/detail?id=1119497721","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119497721?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:50","pubTimestamp":1775047827,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式向一项罕见儿科疾病产品申请的赞助商授予优先审评凭证。这一重要公告发布在联邦公报官方网站上。\n优先审评券计划旨在激励制药企业针对罕见儿科疾病开发创新疗法。获得此凭证的申办方可在后续药物审评中享受加速审评流程的权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142445393","title":"Rocket制药高管透露：公司正就优先审评券出售事宜与外部方积极洽谈","url":"https://stock-news.laohu8.com/highlight/detail?id=1142445393","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142445393?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:02","pubTimestamp":1774616565,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc.高管近日表示，公司正在就优先审评券的出售事宜与多家外部机构展开积极对话。目前相关讨论已进入实质性阶段，双方正就交易细节进行深入沟通。\n优先审评券作为生物制药领域的稀缺资源，能够显著缩短药物审批周期。此次出售计划若顺利推进，将为公司带来可观的非经营性收入，并进一步优化其资金结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135736222","title":"Rocket制药高管称公司正积极与支付方沟通，确保产品上市前获得报销支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1135736222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135736222?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:56","pubTimestamp":1774616180,"startTime":"0","endTime":"0","summary":"Rocket制药公司高管在电话会议中透露，公司正持续与支付方展开对话，旨在为即将上市的产品提前铺平报销通路。这一策略性举措凸显了企业为确保创新疗法商业化成功所做的周密准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135644766","title":"Rocket Pharmaceuticals股价盘前飙升10.2%，美国FDA批准其致命性儿童疾病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1135644766","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135644766?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:20","pubTimestamp":1774614028,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc.股价在盘前交易中大幅上涨10.2%，此前美国食品药品监督管理局（FDA）正式批准了该公司针对一种致命性儿童疾病的新疗法。这一监管里程碑为患者带来了新的希望，同时也显著提升了市场对该公司未来发展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124339996","title":"Rocket Pharmaceuticals 宣布 Kresladi™ 获FDA批准用于治疗严重白细胞黏附缺陷症-I型儿科患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1124339996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124339996?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:01","pubTimestamp":1774609289,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 近日宣布，其基因疗法Kresladi已获得美国食品药品监督管理局的批准，用于治疗患有严重白细胞黏附缺陷症-I型的儿科患者。此次获批标志着针对这一罕见遗传性免疫缺陷疾病的首个基因治疗选择正式问世。Kresladi采用离体慢病毒载体基因疗法，通过改造患者自身的造血干细胞，使其能够正常表达CD18蛋白。该批准为患有这种毁灭性疾病的儿童及其家庭带来了新的希望。Rocket Pharmaceuticals表示将积极推进商业化进程，确保药物尽快惠及符合条件的患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165967031","title":"Rocket制药公司与Cantor Fitzgerald签署销售协议 开展最高1亿美元ATM增发","url":"https://stock-news.laohu8.com/highlight/detail?id=1165967031","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165967031?lang=zh_cn&edition=full","pubTime":"2026-03-11 05:36","pubTimestamp":1773178578,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新备案文件显示，生物技术公司Rocket Pharmaceuticals, Inc.已与知名金融机构Cantor Fitzgerald & Co.正式签署股权销售协议。该协议涉及一项市场发行项目，融资规模最高可达1亿美元。此次合作将赋予Rocket制药公司根据市场条件适时向Cantor Fitzgerald发行和出售普通股的灵活性。作为专注于开发基因疗法治疗罕见病的临床阶段企业，此次融资安排将为Rocket制药推进其创新疗法研发管线提供重要资金支持。该协议细节已通过8-K表格提交美国证券交易委员会备案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517043028","title":"Rocket Pharmaceuticals, Inc.2024财年实现净利润-2.59亿美元，同比减少5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517043028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517043028?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Rocket Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.59亿美元，同比减少5.28%；其中营业收入为0.00美元，每股基本收益为-2.73美元。从资产负债表来看，Rocket Pharmaceuticals, Inc.总负债64.47百万美元，其中短期债务2.86百万美元，资产负债比为0.09，流动比率为0.10。机构评级：截至2025年3月8日，当前有14家机构对Rocket Pharmaceuticals, Inc.目标价做出预测，其中目标均价为39.86美元，其中最低目标价为15.00美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000226abed6696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000226abed6696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517427639","title":"Rocket Pharmaceuticals, Inc.盘中异动 急速上涨5.02%报9.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517427639","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517427639?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:23","pubTimestamp":1741195422,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时23分，Rocket Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.02%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为934.29%、303.67%、291.71%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012342a260f792&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012342a260f792&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668785","title":"Rocket Pharmaceuticals, Inc.盘中异动 下午盘快速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668785?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:09","pubTimestamp":1741032562,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时09分，Rocket Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.03%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4586.34%、212.52%、182.79%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040922abe690da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040922abe690da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516374506","title":"Scotiabank：维持Rocket Pharmaceuticals(RCKT.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由51.00美元调整至52.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516374506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516374506?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Rocket Pharmaceuticals(RCKT.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由51.00美元调整至52.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516742638","title":"加拿大投资银行集团：维持Rocket Pharmaceuticals(RCKT.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至36.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516742638","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516742638?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:41","pubTimestamp":1741005705,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Rocket Pharmaceuticals(RCKT.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至36.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03204148492500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514351191","title":"Rocket Pharmaceuticals(RCKT.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为3.13万美元；每股收益为-0.62美元，前值为-0.64美元，预期值为-0.72美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351191","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514351191?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:54","pubTimestamp":1740696868,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals(RCKT.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为3.13万美元；每股收益为-0.62美元，前值为-0.64美元，预期值为-0.72美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28065448442536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182675192","title":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益$(0.62)超预期$(0.71)","url":"https://stock-news.laohu8.com/highlight/detail?id=1182675192","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182675192?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692337,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益为$(0.62)，超出市场预期的$(0.71)。以上内容来自Benzinga Earnings专栏，原文如下：Rocket Pharmaceuticals Q4 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益$(0.62)超预期$(0.71)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514180850","title":"Rocket Pharmaceuticals, Inc.盘中异动 临近午盘急速上涨5.02%报9.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180850","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514180850?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:37","pubTimestamp":1740587835,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时37分，Rocket Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.02%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5902.90%、215.43%、213.88%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Organovo Holdings, Inc.，振幅分别为181.36%、49.18%、43.31%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270037159893c268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270037159893c268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514501900","title":"Rocket Pharmaceuticals, Inc.盘中异动 早盘大幅下跌5.07%报9.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514501900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514501900?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:20","pubTimestamp":1740500401,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时20分，Rocket Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.07%。截至发稿，该股报9.54美元/股，成交量33.6616万股，换手率0.32%，振幅6.07%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1320.96%、1114.08%、897.28%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002001a2539fbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002001a2539fbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509781357","title":"Rocket Pharmaceuticals, Inc.盘中异动 临近收盘大幅下挫5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509781357?lang=zh_cn&edition=full","pubTime":"2025-02-07 04:54","pubTimestamp":1738875275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日04时54分，Rocket Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.16%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Ocean Biomedical, Inc.较为活跃，换手率分别为7114.19%、1779.44%、202.65%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为125.58%、77.86%、65.64%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045436abc51ee1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045436abc51ee1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rocketpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1029},{"period":"3month","weight":0.4036},{"period":"6month","weight":-0.1247},{"period":"1year","weight":0.195},{"period":"ytd","weight":0.0997}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rocket Pharmaceuticals, Inc.于1999年7月7日根据特拉华州法律注册成立。该公司是一家完全整合的、处于后期阶段的生物技术公司，专注于开发首创、唯一和同类最佳的基因疗法，具有直接的靶向作用机制和明确的临床终点，用于罕见和破坏性疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.061021},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020726},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.084731},{"month":4,"riseRate":0.583333,"avgChangeRate":0.010265},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.043149},{"month":6,"riseRate":0.583333,"avgChangeRate":0.004799},{"month":7,"riseRate":0.583333,"avgChangeRate":0.119654},{"month":8,"riseRate":0.5,"avgChangeRate":-0.009052},{"month":9,"riseRate":0.583333,"avgChangeRate":0.089397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.048247},{"month":11,"riseRate":0.545455,"avgChangeRate":0.014665},{"month":12,"riseRate":0.545455,"avgChangeRate":0.102516}],"exchange":"NASDAQ","name":"Rocket Pharmaceuticals, Inc.","nameEN":"Rocket Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rocket Pharmaceuticals, Inc.,RCKT,Rocket Pharmaceuticals, Inc.股票,Rocket Pharmaceuticals, Inc.股票老虎,Rocket Pharmaceuticals, Inc.股票老虎国际,Rocket Pharmaceuticals, Inc.行情,Rocket Pharmaceuticals, Inc.股票行情,Rocket Pharmaceuticals, Inc.股价,Rocket Pharmaceuticals, Inc.股市,Rocket Pharmaceuticals, Inc.股票价格,Rocket Pharmaceuticals, Inc.股票交易,Rocket Pharmaceuticals, Inc.股票购买,Rocket Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}